Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration: a double-blind, randomised trial.
In a double-blind, randomised trial of 46 outpatients with endoscopically proven chronic duodenal ulceration, 22 were given colloidal bismuth subcitrate (De-Nol, Gist-Brocades) and 24 were given placebo for four weeks. Clinical and laboratory assessment was made after two and four weeks' therapy. Endoscopic healing was demonstrated in 86.5% of patients taking colloidal bismuth tablets and in 25% of patients taking placebo. We observed no clinical or biochemical side effects in either group. These results indicate that colloidal bismuth subcitrate tablets are well tolerated, and are effective in healing chronic duodenal ulcers.
D000328:Adult; D000368:Aged; D001729:Bismuth / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004724:Endoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D011897:Random Allocation; D013607:Tablets
D009942:Organometallic Compounds; D013607:Tablets; C002791:bismuth tripotassium dicitrate; D001729:Bismuth